期刊
CANCER DISCOVERY
卷 3, 期 3, 页码 280-293出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-12-0336
关键词
-
类别
资金
- NIH [5-R21-CA-155992-02, 2T32CA009672-21, R01CA131045-01, P50CA130810-1A]
- Department of Defense Era of Hope grant [W81XWH-08-0110]
- Rich Rogel Fund for Pancreatic Cancer Research
- Doris Duke Charitable Foundation Clinical Scientist Award
- University of Michigan Gastrointestinal (GI) Specialized Programs of Research Excellence (SPORE) Career Development Award
- Lustgarten Foundation Award
Protein kinases represent the most effective class of therapeutic targets in cancer; therefore, determination of kinase aberrations is a major focus of cancer genomic studies. Here, we analyzed transcriptome sequencing data from a compendium of 482 cancer and benign samples from 25 different tissue types, and defined distinct outlier kinases in individual breast and pancreatic cancer samples, based on highest levels of absolute and differential expression. Frequent outlier kinases in breast cancer included therapeutic targets like ERBB2 and FGFR4, distinct from MET, AKT2, and PLK2 in pancreatic cancer. Outlier kinases imparted sample-specific dependencies in various cell lines, as tested by siRNA knockdown and/or pharmacologic inhibition. Outlier expression of polo-like kinases was observed in a subset of KRAS-dependent pancreatic cancer cell lines, and conferred increased sensitivity to the pan-PLK inhibitor BI-6727. Our results suggest that outlier kinases represent effective precision therapeutic targets that are readily identifiable through RNA sequencing of tumors. SIGNIFICANCE: Various breast and pancreatic cancer cell lines display sensitivity to knockdown or pharmacologic inhibition of sample-specific outlier kinases identified by high-throughput transcriptome sequencing. Outlier kinases represent personalized therapeutic targets that could improve combinatorial therapy options. Cancer Discov; 3(3); 280-93. (C) 2013 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据